New N-Heterocyclic Carbene Gold and Platinum Complexes with 1,3-Dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene Ligands for the Treatment of Esophageal Adenocarcinoma
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27042032 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Hindole Ghosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Antineoplastic Agents, Gold. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, National Institute of Health, University of Kansas Cancer Center.
Abstract (Originalsprache)
Encouraged by the promising anticancer activity of a iodidogold(I)-N-heterocyclic carbene (NHC) complex with a 1,3-diethyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene ligand system, a series of new gold(I), gold(III) and platinum(II) complexes coordinated to this ligand system were designed, prepared, and characterized using NMR spectroscopy and mass spectrometry methods. A preliminary anticancer screening of the complexes using four esophageal adenocarcinoma (EAC) cell lines showed promising activities for the cationic triphenylphosphino-NHC-gold(I) and bis-NHC-gold(I) complexes, accompanied by strong antiproliferative, colony-, and spheroid-forming inhibitory effects. The compounds were relatively less toxic to the normal esophageal cell line Het-1A and the monocyte cell line THP-1. Moreover, these compounds induced caspase 3/7 activity and downregulated anti-apoptotic proteins (Bcl-XL, Bcl-2, and Mcl-1) in EAC cells. Further, the cell cycle promoter cyclin D1 was suppressed by these NHC-gold(I) complexes. Finally, we observed strong reactive oxygen species (ROS) induction in EAC cells with NHC-gold(I) complexes 8 and 11.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
- Organic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.
ORCID-Profile: Dileepkumar Veeragoni, Rainer Schobert, Bernhard Biersack, Prasad Dandawate
Förderung
- Deutsche Forschungsgemeinschaft
- National Institute of Health
- University of Kansas Cancer Center
- NIH COBRE program
- Lida L. Moffett Foundation
- KUMC’s Accelerate Cancer Education
Zitieren
APA
Ghosh, H., Rehm, T., Bhattacharyya, S., Lee, M., Veeragoni, D., Schobert, R., Biersack, B., & Dandawate, P. (2026). New N-Heterocyclic Carbene Gold and Platinum Complexes with 1,3-Dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene Ligands for the Treatment of Esophageal Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27042032
Vancouver
Ghosh H, Rehm T, Bhattacharyya S, Lee M, Veeragoni D, Schobert R, et al. New N-Heterocyclic Carbene Gold and Platinum Complexes with 1,3-Dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene Ligands for the Treatment of Esophageal Adenocarcinoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27042032
BibTeX
@article{Ghosh2026,
author = {Ghosh, Hindole and Rehm, Tobias and Bhattacharyya, Sangita and Lee, Miru and Veeragoni, Dileepkumar and Schobert, Rainer and Biersack, Bernhard and Dandawate, Prasad},
title = {New N-Heterocyclic Carbene Gold and Platinum Complexes with 1,3-Dialkyl-4-anisyl-5-(4-chlorophenyl)imidazol-2-ylidene Ligands for the Treatment of Esophageal Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27042032}
}
EUVIMED